A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

Myron Stefan Czuczman; Hans Knecht; Rebecca Auer; Joseph James McKendrick; Nell Sun Chua; Kim Linton; Graham Collins; Sven De Vos; Leanne Holes; Esteban Abella; Gilles A. Sallee

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

Myron Stefan Czuczman
, Hans Knecht
, Rebecca Auer
, Joseph James McKendrick
, Nell Sun Chua
, Kim Linton
, Graham Collins
, Sven De Vos
, Leanne Holes
, Esteban Abella
, Gilles A. Sallee

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	Journal of Clinical Oncology
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Czuczman, M. S., Knecht, H., Auer, R., McKendrick, J. J., Chua, N. S., Linton, K., Collins, G., De Vos, S., Holes, L., Abella, E., & Sallee, G. A. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Journal of Clinical Oncology.

@article{56b4ad5622fe46a4975c08a02039b804,

title = "A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)",

author = "Czuczman, \{Myron Stefan\} and Hans Knecht and Rebecca Auer and McKendrick, \{Joseph James\} and Chua, \{Nell Sun\} and Kim Linton and Graham Collins and \{De Vos\}, Sven and Leanne Holes and Esteban Abella and Sallee, \{Gilles A.\}",

year = "2014",

language = "Undefined",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

}

Czuczman, MS, Knecht, H, Auer, R, McKendrick, JJ, Chua, NS, Linton, K, Collins, G, De Vos, S, Holes, L, Abella, E & Sallee, GA 2014, 'A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)', Journal of Clinical Oncology.

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). / Czuczman, Myron Stefan; Knecht, Hans; Auer, Rebecca et al.
In: Journal of Clinical Oncology, 2014.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

AU - Czuczman, Myron Stefan

AU - Knecht, Hans

AU - Auer, Rebecca

AU - McKendrick, Joseph James

AU - Chua, Nell Sun

AU - Linton, Kim

AU - Collins, Graham

AU - De Vos, Sven

AU - Holes, Leanne

AU - Abella, Esteban

AU - Sallee, Gilles A.

PY - 2014

Y1 - 2014

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613202223&KeyUID=WOS:000358613202223

M3 - Article

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safely or idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)

UN SDGs

Other files and links

Cite this